Bowing to industry pressure, Massachusetts lawmakers on Monday approved a compromise measure that is designed to lower prescription drug spending for the state Medicaid program, although consumer advocates maintain the diluted effort may still achieve its goals.
The initial proposal from Gov. Charlie Baker sought to negotiate supplemental rebates for Medicaid and potentially cite drug makers for violating consumer protection laws for failing to cooperate, a step that generated significant interest from other states seeking solutions to high drug costs. But the final version contains language that notably softens the original approach.
What is it?
STAT Plus is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What’s included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.